Therefore, after tumor formation, mice were exposed to TRAIL, bortezomib, aloperine, aloperine + TRAIL, or aloperine + bortezomib, as described in the ‘Materials and methods.’ Treatment of mice with bortezomib, aloperine, TRAIL, aloperine + TRAIL, or aloperine + bortezomib inhibited tumor growth (P < 0.05) (Figure 6A, B). This evidence concerns the gene TNFSF10 and neoplasm.